Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA ® (narsoplimab-wuug) ...
1d
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results